Quantcast
Last updated on April 18, 2014 at 21:21 EDT

UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients

December 20, 2012

Digital Science Press, Inc. announces UroToday.com is expanding editorial content with more indepth clinical education for the urologists and medical oncologists on immunotherapy treatments for men with metastatic castration-resistant prostate cancer (mCRPC). UroToday publishes two year-end review white papers: Best of Prostate and the Best of mCRPC featuring interviews with prostate cancer experts.

Berkeley, CA (PRWEB) December 19, 2012

Now in its tenth year as an online urology-medical oncology publisher, Digital Science Press, Inc. (DSP) — UroToday.com is expanding key prostate cancer content with two new sections: immunotherapy treatment for men with metastatic castration-resistant prostate cancer; and advances in metastatic castrate-resistant prostate cancer (mCRPC) treatments for urology and oncology nurses.

“Prostate cancer is the most highly read content on the UroToday website,” says Gina Carithers, publisher, DSP. “For our worldwide readership, the disease has many aspects from screening to diagnosis to treatment — some developing and others controversial. For example, we will continue to follow the PSA controversy and report how the evidence continues to evolve regarding the impact of PSA screening on overall survival.” UroToday is also doing more multi-media lectures on the development of new therapies and treatments that enable the urologists and medical oncologists to more effectively treat the metastatic castration-resistant prostate cancer patient.

The web platform for UroToday been upgraded to handle the increase in readership, provides easier navigation, a powerful search using Google and personalized access to the recently posted content by disease topic through daily or weekly UroAlerts. “We made an editorial decision earlier this year to focus on the “art of urology.” At conception, UroToday has reported evidence-based medicine (the science of urology); however, we are seeing a fundamental shift within many urology practices to also emphasize quality of life therapies and resources, more towards what we call the art of urology.”

Case in point, the UroToday mini-lecture series on treatments for advanced prostate cancer has now posted two lectures by medical oncologist Chuck Ryan, MD, UCSF, and one multi-media case-study by Bryan Mehlhaff, MD, Oregon Urology Institute. “The mini-lecture series format for medical professional education has been very well received,” said Carithers. “Our web format is well-suited for the hectic physician schedule and provides virtual access to any registered UroToday reader.”

UroToday has more than 10 years of scientific archived reports, and abstracts representing 33-urology disease categories. Current hot topics include all related prostate diseases and GU cancers, endourological procedures, treatments of stone disease, voiding conditions, sexual dysfunctions and Peyronie´s disease. UroToday supports the CAUTI Challenge providing online access to information about the prevention of CAUTI. In 2013, UroToday will be unveiling a urologic catheter resource center.

UroToday.com known as a urology and medical oncology online resource, released an online and print version of its 2012: Best of Prostate and Best of mCRPC interviews. The “Best of mCRPC” features an interview with Deepak Kapoor, MD, President of LUGPA. Presentation highlights and commentary include Charles J. Ryan, MD; Terry FritzPatrick, OUI administrator; Bryan A. Mehlhaff, MD; and Judd W. Moul, MD. The “Best of Prostate” focuses on the PSA controversy with comments from international experts: Peter T. Scardino, MD; William J. Catalona, MD; Alan J. Wein, MD; Fritz H. Schoder, MD; and Monique Roobol, PhD. A downloadable version of The UroToday 2012: Best of Prostate Cancer Surveillance and Screening and the Best of mCRPC is now available at UroToday.

About UroToday: Gina Carithers, CEO and Publisher, Digital Science Press, Inc. founded the online urologic website in 2003 in Berkeley, CA. This worldwide, medical resource focuses on prostate, bladder and renal cancers and urologic health issues impacting men and women´s health, including catheter selection and infection prevention. UroToday.com represents the largest online urology-oncology community. With more than 50 new content items posted daily, readers can access at no charge, by registering at http://www.urotoday.com. UroToday International Journal (http://www.UIJ.com) is a peer-review online journal, and features articles on all urological topics, including original research, review articles and case studies.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012UroToday/12Best_Of_Prostate_Cancer/prweb10249752.htm


Source: prweb